Fibroblast Growth Factors
- Name
- Fibroblast Growth Factors
- Accession Number
- DBCAT000119
- Description
A family of small polypeptide growth factors that share several common features including a strong affinity for HEPARIN, and a central barrel-shaped core region of 140 amino acids that is highly homologous between family members. Although originally studied as proteins that stimulate the growth of fibroblasts this distinction is no longer a requirement for membership in the fibroblast growth factor family.
- Drugs
Drug Drug Description Palifermin A form of recombinant human keratinocyte growth factor used to prevent and treat oral mucositis following radiation or chemotherapy. Fibroblast growth factor-1 Investigated for use/treatment in coronary artery disease and peripheral vascular disease. Repifermin Investigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease. Basic Fibroblast Growth Factor Basic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications. Trafermin Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers. - Drugs & Drug Targets